Ondrey's Research Program
Area of Focus
I lead a research team whose goal is to find drugs that reduce head and neck cancer incidence while providing screening services for patients with precancerous conditions. Head and neck cancer is a disease with largely increased incidence rates and largely unchanged cure rates for several decades. We formed a comprehensive bench-to-bedside program in 1999 to study head and neck carcinogenesis in the lab and patients to improve understanding of the disease and improve outcomes. The Principal goal is to study treatments and molecular risks for the development of head and neck cancers. These novel concepts are studied in federally credentialed and funded clinical trials in the Active Cancer surveillance program of M Health’s and regional Oral Potentially Malignant Disorders (OPMD) Clinical Program.
AeroCore Testing Service
The AeroCore Inhalation Testing Research Service Facility provides aerosol/vapor exposures to rodent animal models for the purpose of testing the safety and efficacy of inhaled materials. AeroCore was formed with support from the Masonic Cancer Center, College of Pharmacy and the Department of Otolaryngology. Our techniques and services are inspired by the work of Dr. Lee Wattenberg and his innovations in chemoprevention and regional drug delivery.
AeroCore is set up as an Internal/External Sales Organization within the University of Minnesota Department of Otolaryngology. The services are available as ala carte options with a pre-approved cost structure. AeroCore is streamlined to provide a compressed timeline of services from initial contact to project completion. The services are comprehensive to include animal protocol approval (IACUC), handling chemicals of unknown safety, project execution, analytical support, written protocols and documented results with minimal contract negotiation time.
Contact Us
Beverly Wuertz, Laboratory Manager
612-625-3090
Lions Research Building/ McGuire Translational Research Facility
2001 6th Street SE, Minneapolis, MN, 55455
AeroCore Expertise & Information
Aerosol Delivery
Expert Consultant - Timothy Wiedmann, PhD - Professor, Department of Pharmaceutics
Professor Wiedmann's research focuses on the common thread of characterizing the physical-chemical properties of biological systems for optimizing drug delivery. He specializes in inhalation delivery in rodent animal models, including a wide range of compounds for potential application in cancer chemoprevention and chemotherapy, cystic fibrosis, pulmonary arterial hypertension, and lung surfactant for respiratory distress syndrome. Dr. Wiedmann also provides consultation in:
Expert Consultant - Dr. Jayanth Panyam, PhD, Endowed Professor of Targeted Drug Delivery and Department Head, Pharmaceutics
Dr. Panyam’s research is primarily focused on investigating the mechanisms of nanotechnology-based anticancer drug delivery, with emphasis on understanding how various biological factors influence the effectiveness of delivery systems. His ultimate goal is to use the knowledge derived from these studies to devise advanced delivery systems that can be effectively translated to the clinic. Dr. Panyam provides consultation in:
Biomarkers
Expert Consultant - Dr. Timothy Griffin, PhD, Professor & Director, Center for Mass Spectrometry and Proteomics, Biochemistry, Molecular Biology, and Biophysics
Dr. Griffin's research interests focus on the development and application of mass spectrometry-based tools to study proteins and proteomes. The goal of his work is to provide the necessary tools to enable the system-wide characterization of proteins expressed within a cell, tissue, biological fluid or organism, in order to better understand basic mechanisms of biological function and disease.
Microsurgery
Expert Consultant & Facility Director - Frank Ondrey, MD, PhD, FACS- Associate Professor, Department of Otolaryngology
Dr. Ondrey's is a clinician scientist whose research focus is in aerodigestive translational chemoprevention research. Dr. Ondrey has performed several preclinical contracts in chemoprevention of lung cancer using the A/J mouse model and developed animal models for laryngeal carcinogenesis in rodents with Dr. Lee Wattenberg. Dr. Ondrey consults in:
Expert Consultant - Dr. Bevan Yueh, MD, MPH, Department Head & Professor, Department of Otolaryngology - Head and Neck Surgery
Dr. Yueh is a head & neck surgeon, and his practice is focused on the ablation of H&N tumors. As a former Robert Wood Johnson Clinical Scholar, he has expertise in clinical epidemiology and health services research.
Expert Consultant - Dr. Samir Khariwala, MD, Associate Professor & Chief, Division of Head and Neck Surgery, Department of Otolaryngology - Head and Neck Surgery
Dr. Khariwala's primary research areas are biomarkers and outcomes in head and neck cancer and he consults in:
Expert Consultant - Dr. Sobia Khaja, MD, Assistant Professor, Department of Otolaryngology - Head and Neck Surgery
Dr. Khaja specializes in head and neck oncology and microvascular reconstruction.
Expert Consultant - Dr. Sofia Lyford-Pyke, MD, Assistant Professor, Department of Otolaryngology - Head and Neck Surgery
Dr. Lyford-Pyke specializes in facial plastic and reconstructive surgery.
Middle Ear/Sinus
Expert Consultant - Dr. Sebahattin Cureoglu, MD, Associate Professor, Department of Otolaryngology - Head and Neck Surgery
Dr. Cureoglu's research focuses on middle ear infections, hearing loss, otosclerosis, Meniere’s disease, congenital and acquired hearing losses, syndromic ear problems, and other ear pathologies. He has published more than 130 peer-reviewed scientific articles and presented more than 40 presentations in scientific conferences. Dr. Cureoglu consults in:
Expert Consultant - Dr. Tina C Huang, MD, Assistant Professor, Department of Otolaryngology - Head and Neck Surgery
Dr. Huang consults in:
Operations
Facility Director - Dr. Frank G. Ondrey, MD, PhD, FACS
Dr. Ondrey is a clinician-scientist in aerodigestive translational research. He has directed translational studies in clinical chemoprevention for over 15 years at the University of Minnesota and is a longstanding PI for NCI chemoprevention consortium studies. He is co-leader of the Carcinogenesis and Prevention Program for the University of Minnesota Masonic NCI-designated cancer center. His NCI-funded molecular oncology program is geared at aerodigestive cancer prevention including in vitro, animal clinical trials, and human clinical trials. He has studied transcription factor biology cancer for approximately 20 years and was the first to establish upregulation of NFκB as a mechanism for proinflammatory cytokine secretion in his fellowship research at the NIH. He has performed several preclinical contracts in the chemoprevention of lung cancer using the A/J mouse model and developed animal models for laryngeal carcinogenesis in rodents with Dr. Lee Wattenberg.
Animal Colony Manager - Donna Seabloom
Donna supervises the daily care of the animals as well as performing experimental procedures, including carcinogen administration, aerosol delivery, diet administration, and necropsy of animals. She has 18 years of experience in managing the animal colony in Dr. Ondrey’s laboratory. Donna is an expert in many small animal techniques, including injections, gavage, and direct laryngoscopy. Donna's experience in animal handling ensures a low-stress environment for the animals, minimizing experimental variability.
Laboratory Manager - Beverly Wuertz
Beverly, a scientist in AeroCore and Dr. Frank Ondrey's molecular oncology program, has over 15 years of experience in molecular biology and small animal surgery. Beverly coordinates incoming work requests, project summaries, and sales agreements. Together with Donna Seabloom, arranges regulatory compliance for the facility and user projects, day-to-day management of research data, and laboratory administrative processes (including fulfillment of regulatory requirements, and procuring laboratory services and supplies). Beverly performs small animal surgery including murine direct laryngoscopy, maintains equipment, performs necropsy and sample collections, and coordinates the efforts of our expert consultants.
Technical Consultant - Art Galbraith
Art provides technical expertise on aerosol drug delivery equipment and chemistry. Arthur provides support for aerosol exposures and has 40+ years of experience with the design and development of robust equipment and processes. His previous work under Dr. Lee Wattenberg involved inhalation treatments for lung cancer chemoprevention.
Pathology
Expert Consultant - Dr. M. Gerard O'Sullivan, PhD, Professor & Director, Comparative Pathology Shared Resource, Masonic Cancer Center
Dr. O'Sullivan's research interests and consultation expertise are in Cancer chemoprevention; Colon carcinogenesis; Comparative and experimental pathology; Pathology of rodents and non-human primates; Parvovirus infections of animals and human beings.
Representative Projects
Aerosol Delivery
- Lung distribution of the chemopreventive agent difluoromethylornithine (DFMO) following oral and inhalation delivery
- Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles
- Safety and preclinical efficacy of aerosol pioglitazone on lung adenoma prevention in A/J mice
Animal Models
- A method of producing carcinoma in upper digestive tree and esophagus of the Syrian golden hamster using wounding and instillation of N-methylnitrosourea
- Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats
- N-methylnitrosourea-induced carcinoma as a model for laryngeal carcinogenesis
- Ototoxicity after combined platinum and fractioned radiation in a novel guinea pig model
Chemoprevention
- Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethlornithine and 5-fluorouracil
- Fixed-dose combinations of pioglitazone and metformin for lung cancer prevention
Factors Influencing the Progression of Oral Leukoplakia to Squamous Cell Carcinoma
This project seeks to evaluate the natural history and screening practices of oral leukoplakia patients at the University of Minnesota. As a secondary objective, data on risk factors will be collected.
Metformin for Oral Cancer Prevention
This multi-institutional study led by the University of Arizona is a phase IIb randomized, double-blind, placebo-controlled trial in current and former smokers with oral leukoplakia or erythroplakia to explore the potential of metformin for oral cancer prevention. Dr. Ondrey is a regular contributor leading trial participation at the University of Minnesota.
Pioglitazone-Metformin Combination Treatment for High-Risk Oral Preneoplasia
This is a phase IIA chemoprevention study of a pioglitazone-metformin combination generic (15mg/500mg) twice a day for 12 weeks in high-risk oral leukoplakia patients. The clinical and histologic changes of leukoplakia from baseline to the end of the study will be determined.
Phase II Cancer Prevention Trial of the PPAR gamma Agonist Pioglitazone in Oral Leukoplakia: an Interconsortium study (2009-2015)
Efficacy Testing in the Strain A/J Mouse Lung Tumor Model with Selected Chemopreventive Agents Delivered by Liquid Aerosol or in the Diet (2011-2012)
Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol. 2005;114(3):278-283. doi:10.1016/j.clim.2004.12.003
Estensen RD, Anderson WR, Galbraith AR, et al. A method of producing carcinoma in upper aerodigestive tree and esophagus of the Syrian golden hamster using wounding and instillation of N-methylnitrosourea. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1644-1650. doi:10.1158/1055-9965.EPI-06-1075
Djalilian HR, Lessan K, Grami V, et al. A new immune-competent animal model of mucosally derived squamous cell carcinoma. Otolaryngol Head Neck Surg. 2004;131(5):781-783. doi:10.1016/j.otohns.2004.01.014
Johnston N, Ondrey F, Rosen R, et al. Airway reflux. Ann N Y Acad Sci. 2016;1381(1):5-13. doi:10.1111/nyas.13080
Archibald H, Buryska S, Ondrey FG. An active surveillance program in oral preneoplasia and translational oncology benefit. Laryngoscope Investig Otolaryngol. 2021;6(4):764-772. doi:10.1002/lio2.612
Tsuchiya K, Kim Y, Ondrey FG, Lin J. Characterization of a temperature-sensitive mouse middle ear epithelial cell line. Acta Otolaryngol. 2005;125(8):823-829. doi:10.1080/00016480510031533
Galbraith AR, Seabloom DE, Wuertz BR, et al. Chemoprevention of Lung Carcinogenesis by Dietary Nicotinamide and Inhaled Budesonide. Cancer Prev Res (Phila). 2019;12(2):69-78. doi:10.1158/1940-6207.CAPR-17-0402
Rohrer J, Wuertz BRK, Ondrey F. Cigarette smoke condensate induces nuclear factor kappa-b activity and proangiogenic growth factors in aerodigestive cells. Laryngoscope. 2010;120(8):1609-1613. doi:10.1002/lary.20972
Elton AC, Ondrey FG. Commentary on the letter to the editor regarding “reflux symptoms may develop in cases of throat mucosa injury, stress and related-autonomic nerve dysfunction.”. Am J Otolaryngol. 2023;44(1):103688. doi:10.1016/j.amjoto.2022.103688
Flanagan CE, Rhodus NL, Cole KA, Szabo E, Ondrey FG. Correlation analysis of oral lesion sizes by various standardized criteria. Am J Otolaryngol. 2016;37(6):502-506. doi:10.1016/j.amjoto.2016.07.004
Pearson SE, Meyer AC, Adams GL, Ondrey FG. Decreased hearing after combined modality therapy for head and neck cancer. Am J Otolaryngol. 2006;27(2):76-80. doi:10.1016/j.amjoto.2005.07.008
Le MN, Wuertz BR, Biel MA, Thompson RL, Ondrey FG. Effects of methylene blue photodynamic therapy on oral carcinoma and leukoplakia cells. Laryngoscope Investig Otolaryngol. 2022;7(4):982-987. doi:10.1002/lio2.772
Hall JA, Rusten M, Abughazaleh RD, et al. Effects of PPAR-γ agonists on oral cancer cell lines: Potential horizons for chemopreventives and adjunctive therapies. Head Neck. 2020;42(9):2542-2554. doi:10.1002/hed.26286
Djalilian HR, Caicedo E, Lessan K, et al. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. Cancer Immunol Immunother. 2007;56(8):1207-1214. doi:10.1007/s00262-006-0271-2
Caicedo-Granados EE, Wuertz BR, Ondrey FG. Enforced expression of nuclear factor kappa B in p53 deficient keratinocytes induces cell cycle, angiogenic potential and tumorigenesis. Oral Oncol. 2012;48(4):303-310. doi:10.1016/j.oraloncology.2011.11.008
Swenson W, Miller KA, Wuertz B, Jungbauer WNJ, Ondrey FG. Establishment and characterization of an inverted papilloma-associated sinonasal squamous cell carcinoma cell line. Int Forum Allergy Rhinol. 2021;11(5):938-940. doi:10.1002/alr.22739
Carlson M, Wuertz B, Lin J, Taylor R, Ondrey F. Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck. Int J Otolaryngol. 2009;2009:649615. doi:10.1155/2009/649615
Li W, Wang C, Juhn SK, Ondrey FG, Lin J. Expression of fibroblast growth factor binding protein in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009;135(9):896-901. doi:10.1001/archoto.2009.121
Seabloom DE, Galbraith AR, Haynes AM, et al. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. Cancer Prev Res (Phila). 2017;10(2):116-123. doi:10.1158/1940-6207.CAPR-16-0232
Wright SK, Wuertz BR, Harris G, et al. Functional activation of PPARγ in human upper aerodigestive cancer cell lines. Mol Carcinog. 2017;56(1):149-162. doi:10.1002/mc.22479
Patel KJ, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. Genes associated with early development, apoptosis and cell cycle regulation define a gene expression profile of adenoid cystic carcinoma. Oral Oncol. 2006;42(10):994-1004. doi:10.1016/j.oraloncology.2005.12.017
Koenigsberg C, Ondrey FG. Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway. Anticancer Res. 2020;40(10):5417-5421. doi:10.21873/anticanres.14551
Ozeki M, Hamajima Y, Feng L, Ondrey FG, Schlentz E, Lin J. Id1 induces the proliferation of cochlear sensory epithelial cells via the nuclear factor-kappaB/cyclin D1 pathway in vitro. J Neurosci Res. 2007;85(3):515-524. doi:10.1002/jnr.21133
Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 2004;64(1):55-63. doi:10.1158/0008-5472.can-03-2144
King TA, Ghazaleh RA, Juhn SK, Adams GL, Ondrey FG. Induction of heat shock protein 70 inhibits NF-kappa-B in squamous cell carcinoma. Otolaryngol Head Neck Surg. 2005;133(1):70-79. doi:10.1016/j.otohns.2004.04.038
Lesnick A, Samuels TL, Seabloom D, et al. Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling. Laryngoscope Investig Otolaryngol. 2024;9(1):e1219. doi:10.1002/lio2.1219
Gutkind JS, Molinolo AA, Wu X, et al. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions. JCI Insight. 2021;6(17). doi:10.1172/jci.insight.147096
Lin J, Guan Z, Wang C, et al. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res. 2010;16(1):77-87. doi:10.1158/1078-0432.CCR-08-2362
Janus SC, Weurtz B, Ondrey FG. Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma. Laryngoscope. 2007;117(8):1381-1388. doi:10.1097/MLG.0b013e3180679e59
Hilton CW, Ondrey FG, Wuertz BR, Levine SC. Interleukin-8 production in response to tumor necrosis factor-alpha by cholesteatoma keratinocytes in cell culture. Laryngoscope. 2011;121(2):372-374. doi:10.1002/lary.21352
Elton A, Van Beck J, Li B, Ondrey FG. Large cell neuroendocrine carcinoma originating in the subglottic larynx. Ear Nose Throat J. Published online April 27, 2022:1455613211054628. doi:10.1177/01455613211054628
Unger GM, Kren BT, Korman VL, et al. Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma. Mol Cancer Ther. 2014;13(8):2018-2029. doi:10.1158/1535-7163.MCT-14-0166
Elton AC, Schutte D, Ondrey G, Ondrey FG. Medical scribes improve documentation consistency and efficiency in an otolaryngology clinic. Am J Otolaryngol. 2022;43(4):103510. doi:10.1016/j.amjoto.2022.103510
Elton AC, Cedarstrom V, Quraishi A, et al. Metabolic and Metabolomic Effects of Metformin in Murine Model of Pulmonary Adenoma Formation. Nutr Cancer. 2023;75(3):1014-1027. doi:10.1080/01635581.2023.2165692
Patel A, Miller L, Ahmed K, Ondrey F. NF-Kappa-B downregulation strategies in head and neck cancer treatment. Otolaryngol Head Neck Surg. 2004;131(3):288-295. doi:10.1016/j.otohns.2004.03.004
Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005;29(1):42-45. doi:10.1016/j.cdp.2004.10.003
Elton AC, Severson EP, Ondrey FG, Opperman DA. Observations of increased gastroesophageal reflux symptomology in an anhydrous ammonia exposed population. Am J Otolaryngol. 2022;43(5):103604. doi:10.1016/j.amjoto.2022.103604
Johnston N, Samuels TL, Goetz CJ, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023;133 Suppl 1(Suppl 1):S1-S11. doi:10.1002/lary.30242
Archibald H, Kalland K, Kuehne A, Ondrey F, Roby B, Jakubowski L. Oral Premalignant and Malignant Lesions in Fanconi Anemia Patients. Laryngoscope. 2023;133(7):1745-1748. doi:10.1002/lary.30370
Miller MW, Riedel G, Hoistad D, et al. Ototoxicity after combined platinum and fractionated radiation in a novel guinea pig model. Am J Otolaryngol. 2009;30(1):1-7. doi:10.1016/j.amjoto.2007.12.003
Thompson R, Haws J, Rhodus NL, Ondrey FG. Patients with oral preneoplastic lesions and integration of dental pathology referrals. Am J Otolaryngol. 2022;43(1):103270. doi:10.1016/j.amjoto.2021.103270
Johnston N, Dettmar PW, Ondrey FG, Nanchal R, Lee SH, Bock JM. Pepsin: biomarker, mediator, and therapeutic target for reflux and aspiration. Ann N Y Acad Sci. 2018;1434(1):282-289. doi:10.1111/nyas.13729
Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res. 2009;15(1):2-8. doi:10.1158/1078-0432.CCR-08-0326
Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735-2743. doi:10.1200/JCO.2013.54.6309
Ondrey FG. Pioglitazone, Nuclear Receptors, and Aerodigestive Prevention. Cancer Prev Res (Phila). 2019;12(10):641-644. doi:10.1158/1940-6207.CAPR-19-0341
Tsuchiya K, Toyama K, Tsuprun V, et al. Pneumococcal peptidoglycan-polysaccharides induce the expression of interleukin-8 in airway epithelial cells by way of nuclear factor-kappaB, nuclear factor interleukin-6, or activation protein-1 dependent mechanisms. Laryngoscope. 2007;117(1):86-91. doi:10.1097/01.mlg.0000244182.81768.31
Buryska S, Patel K, Wuertz B, Gaffney PM, Ondrey F. Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality. Anticancer Res. 2023;43(12):5299-5310. doi:10.21873/anticanres.16733
Harris G, Ghazallah RA, Nascene D, Wuertz B, Ondrey FG. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR. Otolaryngol Head Neck Surg. 2005;133(5):695-701. doi:10.1016/j.otohns.2005.07.019
Handley N, Eide J, Taylor R, Wuertz B, Gaffney P, Ondrey F. PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques. Laryngoscope. 2017;127(4):E124-E131. doi:10.1002/lary.26423
Miller WA, Wuertz BR, Ondrey FG. PPARγ-Mediated p21 Induction in Aerodigestive Preneoplastic Cell Lines. Ann Otol Rhinol Laryngol. 2018;127(10):677-686. doi:10.1177/0003489418787833
Rosas RR, Nachbor KM, Handley N, et al. Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention. Head Neck. 2022;44(3):661-671. doi:10.1002/hed.26959
Johnston BNA, Preciado DA, Ondrey FG, Daly KA. Presence of otitis media with effusion and its risk factors affect serum cytokine profile in children. Int J Pediatr Otorhinolaryngol. 2008;72(2):209-214. doi:10.1016/j.ijporl.2007.10.005
Preciado D, Caicedo E, Jhanjee R, et al. Pseudomonas aeruginosa lipopolysaccharide induction of keratinocyte proliferation, NF-kappa B, and cyclin D1 is inhibited by indomethacin. J Immunol. 2005;174(5):2964-2973. doi:10.4049/jimmunol.174.5.2964
Yang Y, Rhodus NL, Ondrey FG, et al. Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker. PLoS One. 2014;9(4):e95389. doi:10.1371/journal.pone.0095389
de Jong EP, Xie H, Onsongo G, et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. PLoS One. 2010;5(6):e11148. doi:10.1371/journal.pone.0011148
Rosas R, Buryska S, Silver R, Wuertz B, Ondrey F. Retinoids Augment Thiazolidinedione PPARγ Activation in Oral Cancer Cells. Anticancer Res. 2020;40(6):3071-3080. doi:10.21873/anticanres.14288
Seabloom DE, Galbraith AR, Haynes AM, et al. Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice. Cancer Prev Res (Phila). 2017;10(2):124-132. doi:10.1158/1940-6207.CAPR-16-0174
Ondrey FG, Moldestad E, Mastroianni MA, et al. Sensorineural hearing loss in Vogt-Koyanagi-Harada syndrome. Laryngoscope. 2006;116(10):1873-1876. doi:10.1097/01.mlg.0000234946.31603.fe
Rhodus NL, Cheng B, Ondrey F. Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus. Mediators Inflamm. 2007;2007:19854. doi:10.1155/2007/19854
Caicedo-Granados EE, Wuertz BR, Marker PH, Lee GS, Ondrey FG. The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition. Arch Otolaryngol Head Neck Surg. 2011;137(8):799-805. doi:10.1001/archoto.2011.131
Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005;44(2):77-82. doi:10.1002/mc.20113
Juhn SK, Jung MK, Hoffman MD, et al. The role of inflammatory mediators in the pathogenesis of otitis media and sequelae. Clin Exp Otorhinolaryngol. 2008;1(3):117-138. doi:10.3342/ceo.2008.1.3.117
Wuertz BR, Darrah L, Wudel J, Ondrey FG. Thiazolidinediones abrogate cervical cancer growth. Exp Cell Res. 2017;353(2):63-71. doi:10.1016/j.yexcr.2017.02.020
Hohberger L, Wuertz BRK, Xie H, Griffin T, Ondrey F. TNF-alpha drives matrix metalloproteinase-9 in squamous oral carcinogenesis. Laryngoscope. 2008;118(8):1395-1399. doi:10.1097/MLG.0b013e318174e09b
Swenson WG, Wuertz BRK, Ondrey FG. Tobacco carcinogen mediated up-regulation of AP-1 dependent pro-angiogenic cytokines in head and neck carcinogenesis. Mol Carcinog. 2011;50(9):668-679. doi:10.1002/mc.20775
Buryska S, Arji S, Wuertz B, Ondrey F. Using Bland-Altman Analysis to Identify Appropriate Clonogenic Assay Colony Counting Techniques. Technol Cancer Res Treat. 2023;22:15330338231214250. doi:10.1177/15330338231214250
Meet the Team
Research in Action
